Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

Inclusion Criteria

• •Signed informed consent.
• •Female, ≥ 18 and ≤ 70 years.
• •Histologically confirmed invasive breast cancer.
• •Metastatic breast cancer.
• •ECOG Performance Status of 0 to 2.
• •Life expectancy of more than 3 months.
• •Subject must have adequate organ function.
• •Normal laboratory values: hemoglobin \> 90g/dl, neutrophils \> 1.5×10\^9/L, platelets \> 80×10\^9/L, serum creatinine \< 1.5×upper limit of normal (ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN.
• •Negative serum pregnancy test for women with childbearing potential.
• •Good conditions for infusion and willing to have phlebotomy throughout whole study.
• •Have ceased anti-tumor treatments including endocrinotherapy and bio-targeted therapy for more than 28 days.
• •Have at least one target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.